eFFECTOR Therapeutics, Inc.
Cash in trust
$175M
$175,008,104
Trust per share
$10.18
Redemption value
IPO
Jan 2021
$172M raised
Combination deadline
—
Not disclosed
Filings on record
381
Latest Aug 2, 2024
Business combination
- Target
- Not disclosed in an indexed filing
- Announced
- May 27, 2021
- Closed
- Aug 31, 2021
Overview
eFFECTOR Therapeutics, Inc. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001828522. It completed its initial public offering in Jan 2021, raising $172M in gross proceeds. The vehicle is sponsored by eFFECTOR Therapeutics. The mandate targets healthcare. Business combination closed; the company trades under a new ticker.
“we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare related industries in the United States and Europe.”
Reading the filings
Arithmetic on what eFFECTOR Therapeutics, Inc. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.
Trust versus the $10 unit
The trust holds $10.18 per public share, 1.8% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.
Warrant coverage
Each unit carried one-third warrant per unit. Warrants are dilution deferred: they cost the holder nothing until exercised, and they overhang the post-combination share count. Thinner coverage is generally a sign of a stronger book at pricing.
Sponsor record
eFFECTOR Therapeutics has launched 2 vehicles. Of the 2 that have resolved, 2 closed a combination and 0 liquidated, a 100% completion rate. A sponsor's record is not a forecast, but it does tell you whether the team has taken a deal across the line before.
Underwriting
Cantor Fitzgerald led the offering. It has been named on 151 SPAC IPOs, book-running 130 of them, and 69.8% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.
Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.
381 filings in all. 22 in the last three months, against a busiest month of 39.
News on eFFECTOR Therapeutics, Inc.
Last 90 daysNothing in the last 90 days that names this vehicle. We attribute a story only when the release carries the ticker or the registered name, so an empty section means no press release or wire story matched — not that nothing was published. The filings below are the primary record either way.
SEC filing history
Free tier: filings older than 24 hours- EFFECT
Notice of effectiveness
Accession 9999999995-24-002352
- EFFECT
Notice of effectiveness
Accession 9999999995-24-002349
- EFFECT
Notice of effectiveness
Accession 9999999995-24-002348
- EFFECT
Notice of effectiveness
Accession 9999999995-24-002347
- 15-12G
Deregistration of securities
Accession 0001193125-24-188900
- S-8 POS
S-8 POS
Accession 0001193125-24-188897
- S-8 POS
S-8 POS
Accession 0001193125-24-188875
- POS AM
POS AM
Accession 0001193125-24-188868
- POS AM
POS AM
Accession 0001193125-24-188859
- POS AM
POS AM
Accession 0001193125-24-188848
- POS AM
POS AM
Accession 0001193125-24-188836
- 25-NSE
Notification of delisting
Accession 0001354457-24-000516
- 8-K
Current report
Item 2.04 · Accession 0000950170-24-077530
- 8-K
Notice of delisting or failure to satisfy a listing rule
Item 3.01 · Accession 0000950170-24-077420
- 8-K
Other events
Items 2.05, 5.02, 8.01, 9.01 · Accession 0001193125-24-166275
- 8-K
Submission of matters to a vote of security holders
Items 5.03, 5.07, 9.01 · Accession 0001193125-24-161574
- 4
Statement of changes in beneficial ownership
Accession 0000950170-24-073213
- 4
Statement of changes in beneficial ownership
Accession 0000950170-24-073209
- 4
Statement of changes in beneficial ownership
Accession 0000950170-24-073204
- 4
Statement of changes in beneficial ownership
Accession 0000950170-24-073202
- 4
Statement of changes in beneficial ownership
Accession 0000950170-24-073199
- 4
Statement of changes in beneficial ownership
Accession 0000950170-24-073195
- 8-K
Other events
Item 8.01 · Accession 0001193125-24-142277
- 424B3
Prospectus supplement
Accession 0001193125-24-141857
- 8-K
Notice of delisting or failure to satisfy a listing rule
Item 3.01 · Accession 0001193125-24-141847
- 4
Statement of changes in beneficial ownership
Accession 0000950170-24-061597
- 4
Statement of changes in beneficial ownership
Accession 0000950170-24-061593
- SC 13D/A
SC 13D/A
Accession 0001193125-24-137200
- 424B5
424B5
Accession 0001193125-24-135382
- 424B3
Prospectus supplement
Accession 0000950170-24-057204
Pro
Track eFFECTOR Therapeutics, Inc. without the delay
Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.
- Filings live, no 24-hour delay
- One click through to the source document
- Deadline calendar out to 12 months
- CSV export, API and MCP access
Cancel any time. Billed monthly in USD.
eFFECTOR Therapeutics, Inc.: questions answered
What is eFFECTOR Therapeutics, Inc.?
eFFECTOR Therapeutics, Inc. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001828522. It completed its initial public offering in Jan 2021, raising $172M in gross proceeds. The vehicle is sponsored by eFFECTOR Therapeutics. The mandate targets healthcare. Business combination closed; the company trades under a new ticker.
How much does eFFECTOR Therapeutics, Inc. hold in trust?
Approximately $175,008,104, or about $10.18 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.
When must eFFECTOR Therapeutics, Inc. complete a merger?
No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.
What happens if eFFECTOR Therapeutics, Inc. does not find a target in time?
The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.
Can I redeem shares in eFFECTOR Therapeutics, Inc., and at what price?
Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.18 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.
Is the trust value the same as the share price for eFFECTOR Therapeutics, Inc.?
No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.
How much dilution do eFFECTOR Therapeutics, Inc.'s founder shares and warrants create?
Each unit also carried one-third warrant per unit, which is dilution deferred until exercise. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.
Who sponsors eFFECTOR Therapeutics, Inc., and what is their track record?
eFFECTOR Therapeutics is the sponsor entity, part of the eFFECTOR Therapeutics franchise. That franchise has launched 2 vehicles in total, of which 2 closed a combination and 0 liquidated, a 100% completion rate on resolved vehicles. Named principals: Brian G. Atwood, Chris Ehrlich.
Which banks underwrote the eFFECTOR Therapeutics, Inc. IPO?
Cantor Fitzgerald. Cantor Fitzgerald was credited as book-running manager on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.
Is eFFECTOR Therapeutics, Inc. a good investment?
That is not a question this site answers. eFFECTOR Therapeutics, Inc. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.
Where does this eFFECTOR Therapeutics, Inc. data come from?
Filings eFFECTOR Therapeutics, Inc. submitted to the SEC under CIK 0001828522: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.
Compiled by the SPACListing research desk
Last reconciled Oct 31, 2026
Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.
Read the full methodology · What is in the dataset · Report a correction
SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.
Continue reading
The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.
eFFECTOR Therapeutics: the full record
Every vehicle this sponsor has launched, what closed, what liquidated and what is still live.
Cantor Fitzgerald in SPACs
Mandates, bookrun credit, deal volume and the outcome of the vehicles it priced.
Healthcare SPACs
Every vehicle chasing the same mandate, ranked by cash in trust.
All completed de-spac transactions
Business combination closed; the company trades under a new ticker.
Deadline calendar
Which sponsors are running out of time, and when the extension votes land.
What is a SPAC?
The structure, the economics and where the risks actually sit.
SPAC glossary
Every term in a blank-check filing, defined the way practitioners use it.
How this data is built
Coverage universe, ingestion, normalisation, lifecycle classification and known limits.